

# CONTENTS

---

	<b>Page No.</b>
List of Tables	<b>ix</b>
List of Figures	<b>xii</b>
List of Abbreviations	<b>xvii</b>
Preface of the Thesis	<b>xix</b>

---

<b>1. INTRODUCTION</b>	<b>1-10</b>
------------------------	-------------

---

1.1	Background	1
1.2	Problem statement and Research motivation	1
1.3	Aim and Objective of the present thesis work	6
1.4	Research Contributions of the present thesis work	7
1.5	Outcome of the present thesis work	7
1.6	Thesis Organization	8

---

<b>2. LITERATURE REVIEW</b>	<b>11-51</b>
-----------------------------	--------------

---

2.1	Overview	12
2.2	Classification of Diabetes Mellitus (DM)	12
2.2.1	Pre-diabetics with Impaired Glucose Tolerance (IGT) and Impaired Fasting Glucose (IFG) Conditions	12
2.3	Complications associated with Diabetes Mellitus (DM)	13
2.4	Monitoring Blood Glucose Levels	13
2.4.1	Invasive technique based approach	13
2.4.1.2	User-Friendly Invasive Blood Glucose Meters	14
2.4.2	Semi-invasive technique based approach	16
2.4.3	Non-invasive technique based approaches	17
2.5	Noninvasive optical and other technologies for blood glucose level measurements	17
2.5.1	Fluorescent Spectroscopy	17
2.5.1.1	Significance	18
2.5.1.2	Limitations	18
2.5.2	Photo Acoustic (PA) Spectroscopy	19
2.5.2.1	Significance	20
2.5.2.2	Limitations	20
2.5.3	Optical Coherence Tomography (OCT)	20
2.5.3.1	Significance	21

2.5.3.2	Limitations	21
2.5.4	Polarization Spectroscopy	21
2.5.4.1	Significance	22
2.5.4.2	Limitations	23
2.5.5	Ocular Spectroscopy	23
2.5.5.1	Significance	23
2.5.5.2	Limitations	23
2.5.6	Raman Spectroscopy	23
2.5.6.1	Significance	24
2.5.6.2	Limitations	24
2.5.7	Occlusion Spectroscopy	25
2.5.7.1	Significance	25
2.5.7.2	Limitations	25
2.5.8	Bio-impedance Spectroscopy	25
2.5.8.1	Significance	26
2.5.8.2	Limitations	26
2.5.9	Electromagnetic Sensing	26
2.5.9.1	Significance	27
2.5.9.2	Limitations	27
2.5.10	Reverse Iontophoresis	27
2.5.10.1	Significance	27
2.5.10.1	Limitations	27
2.5.11	Mid-Infrared (MIR) Spectroscopy	28
2.5.11.1	Significance	29
2.5.11.2	Limitations	29
2.5.12	Near Infrared (NIR) Spectroscopy	29
2.5.12.1	Significance	30
2.5.12.2	Limitations	31
2.5.13	Thermal Spectroscopy	31
2.5.13.1	Significance	31
2.5.13.2	Limitations	31
2.5.14	Ultrasound Modulated Optical Technique	31
2.5.14.1	Significance	32
2.5.14.2	Limitations	32
2.6	Various developing Noninvasive Glucometers and their respective Approval status	36
2.6.1	Gluco-Track™ by Integrity Applications Ltd., Ashkelon, Israel	36
2.6.2	Portable Blood Glucose meter by Glove Instruments, USA	36
2.6.3	Noninvasive Glucometer based on Microwave Technology by Baylor University, Texas, USA	36

<b>2.6.4</b>	Noninvasive Glucometer based on Near Infrared Optical Spectroscopy and Multivariate Tools by InLight Solutions, Albuquerque, New Mexico, USA	<b>36</b>
<b>2.6.5</b>	Noninvasive Glucometer by LighTouch Medical Inc., Pennsylvania, USA	<b>37</b>
<b>2.6.6</b>	I-Sugar-X Noninvasive Glucometer by Freedom Meditech Inc., California, USA	<b>37</b>
<b>2.6.7</b>	Contact Lens based Continuous Glucose Monitoring by University of Washington, USA	<b>37</b>
<b>2.6.8</b>	Symphony tCGM by Echo Therapeutics Inc., Philadelphia, USA	<b>37</b>
<b>2.6.9</b>	Multisensory Glucose Monitoring System by Biovotion AG, Zürich, Switzerland	<b>38</b>
<b>2.6.10</b>	TensorTip CoG-Combo Glucometer by Cnoga Medical Ltd., Akiva, Israel	<b>38</b>
<b>2.6.11</b>	Noninvasive Glucometer by C8 Medisensors by California-based Company, USA	<b>38</b>
<b>2.6.12</b>	Easy Check Positive ID (Identification) Noninvasive Glucometer by Positive ID Corporation, the Israel-based Company	<b>38</b>
<b>2.6.13</b>	Eye sense Noninvasive Glucometer by EyeSense GmbH, Großostheim, Germany	<b>39</b>
<b>2.6.14</b>	Glucoband Noninvasive Glucometer by Calisto Medical Inc., Texas, USA	<b>39</b>
<b>2.6.15</b>	Occlusion Spectroscopy based Noninvasive Glucometer by OrSense Ltd., Petah-Tikva, Israel	<b>39</b>
<b>2.6.16</b>	Noninvasive Glucose monitoring device by Biosensor Inc., Newyork, USA	<b>39</b>
<b>2.6.17</b>	ClearPath DS-120 by Freedom Meditech, Inc., California, USA	<b>40</b>
<b>2.6.18</b>	TANGTEST Blood Glucose Meter based on Optical Technology, USA	<b>40</b>
<b>2.6.19</b>	Reverse Iontophoresis based Glucose Monitoring Device (RIGMD), Seoul, Korea	<b>40</b>
<b>2.6.20</b>	Aprise by Glucon Inc., Colorado, USA	<b>41</b>
<b>2.6.21</b>	Sentris-100 by GlucoLight Corporation, Pennsylvania, USA	<b>41</b>
<b>2.7</b>	Noninvasive Glucometer Devices that received Regulatory Approvals	<b>41</b>
<b>2.7.1</b>	Diasensor, BICO Inc., Pittsburgh, USA	<b>41</b>
<b>2.7.2</b>	Pendra by Pendragon Medical Ltd., Zurich, Switzerland	<b>42</b>
<b>2.7.3</b>	Glucowatch by Cygnus Inc., California, USA	<b>42</b>
<b>2.7.4</b>	SCOUT DS system by Vera Light Inc., Manitoba, Canada	<b>43</b>
<b>2.8</b>	Blood glucose	<b>43</b>
<b>2.8.1</b>	Nutritional carbohydrates	<b>43</b>

2.8.2	Physiological regulation of blood glucose levels	44
2.8.3	Glucose	44
2.9	Human skin tissue	45
2.10	Human fingertip	46
2.11	Optical clearing effect related studies	46
2.12	In-vitro experiments	46
2.13	In-vivo experiments	47
2.13.1	OGTT (Oral Glucose Tolerance Test)	47
2.13.2	HbA1c (Glycated Hemoglobin) levels impact over the blood glucose levels	47
2.13.3	Blood glucose level and blood pressure related studies	48
2.14	Additional effects	49
2.14.1	Machine and Time drift effects	49
2.14.2	Temperature effect	49
2.14.3	Contact interface	50
2.14.4	Location of the body	50
2.15	Conclusion	51

---

### **3. CONCEPT, PROTOTYPE FABRICATION, AND METHODOLOGY** **52-98**

---

3.1	Concept for noninvasive blood glucose measurement	53
3.1.1	Absorption spectral analysis	54
3.2	Prototype fabrication	55
3.2.1	Ultrasound frequency selection	55
3.2.2	Light wavelength selection	56
3.3	In-vitro analysis	61
3.3.1	Glucose molecule specificity analysis	61
3.3.2	Glucose molecule sensitivity analysis at 940 nm	62
3.4	Amplitude Modulation (AM) concept and its application in our work	63
3.5	Fabricated prototype descriptions	67
3.5.1	Modulating signal	68
3.5.2	Carrier wave	70
3.5.3	Modulator unit	72
3.5.3.1	Functional descriptions	72
3.5.4	Ultra Sound Transmitter (UST) and Ultra Sound Receiver (USR) units	75
3.5.5	Finger holder unit (Finger probe)	77
3.5.6	Synchronous square wave generator	78
3.5.7	Infrared light source	79
3.5.7.1	940 nm LED wavelength verification	79
3.5.8	Infrared (IR) detector (Photodiode)	80

3.5.9	Signal processing unit	81
3.5.10	Result display	81
3.6	In-vitro experiment	81
3.6.1	In-vitro experiment using glucose in distill water	81
3.6.1.1	Result analysis	82
3.6.2	In-vitro experiment using quasi-finger system	82
3.6.2.1	Study subjects	82
3.6.2.2	Sample preparation	83
3.6.2.3	Result analysis	84
3.7	Preliminary in-vivo analysis	84
3.7.1	Extended in-vivo clinical study	86
3.7.2	Study subjects	86
3.7.3	Experimental phases	87
3.7.3.1	Phase I (a): Before meal intake session in absence of amplitude modulated ultrasound in our prototype	87
3.7.3.2	Phase I (b): Before meal intake Session in presence of amplitude modulated ultrasound in our prototype	88
3.7.3.3	Phase II: One hour after meal intake session in presence of amplitude modulated ultrasound in our prototype	89
3.7.4	Result analysis	91
3.8	Calibration	91
3.9	Inference	92
3.10	Tests methodology	92
3.11	Clarke Error Grid analysis	95
3.12	Statistical analysis	97

---

#### **4. EFFECT OF GLUCOSE CONCENTRATION ON LIGHT TRANSMISSION**

**99-109**

---

4.1	Introduction	100
4.2	Study subjects	101
4.3	Experimental protocol	101
4.4	Peak to peak amplitude measurements for Absolute and Square value calculations	103
4.4.1	Absolute value calculations	103
4.4.2	Square value calculations	105
4.4.3	Result and Discussion	106
4.5	Conclusion	109

<b>5.1</b>	<b>Oral Glucose Tolerance Test based clinical study over healthy non-diabetic subjects</b>	<b>111</b>
<b>5.1.1</b>	<b>Introduction</b>	<b>111</b>
<b>5.1.2</b>	<b>Study subjects</b>	<b>111</b>
<b>5.1.3</b>	<b>Experimental protocol</b>	<b>111</b>
<b>5.1.4</b>	<b>Blood glucose measurement</b>	<b>112</b>
<b>5.1.5</b>	<b>Result and Discussion</b>	<b>112</b>
<b>5.1.6</b>	<b>Conclusion</b>	<b>118</b>
<b>5.2</b>	<b>The effect of different glucose concentrations over blood glucose levels</b>	<b>118</b>
<b>5.2.1</b>	<b>Introduction</b>	<b>118</b>
<b>5.2.2</b>	<b>Study subjects</b>	<b>118</b>
<b>5.2.3</b>	<b>Experimental protocol</b>	<b>119</b>
<b>5.2.4</b>	<b>Blood glucose measurement</b>	<b>119</b>
<b>5.2.5</b>	<b>Result and Discussion</b>	<b>120</b>
<b>5.2.6</b>	<b>Conclusion</b>	<b>124</b>
<b>5.3</b>	<b>Study over pre-diabetic subjects</b>	<b>124</b>
<b>5.3.1</b>	<b>Introduction</b>	<b>124</b>
<b>5.3.2</b>	<b>Glucose sensing in pre-diabetics</b>	<b>125</b>
<b>5.3.3</b>	<b>Study subjects</b>	<b>125</b>
<b>5.3.4</b>	<b>Experimental protocol</b>	<b>125</b>
<b>5.3.5</b>	<b>Blood glucose measurement</b>	<b>126</b>
<b>5.3.6</b>	<b>Result and Discussion</b>	<b>126</b>
<b>5.3.7</b>	<b>Conclusion</b>	<b>130</b>
<b>5.4</b>	<b>Clinical study over Diabetic subjects</b>	<b>130</b>
<b>5.4.1</b>	<b>Introduction</b>	<b>130</b>
<b>5.4.2</b>	<b>Blood glucose supervision</b>	<b>131</b>
<b>5.4.3</b>	<b>Study subjects</b>	<b>131</b>
<b>5.4.4</b>	<b>Experimental protocol</b>	<b>131</b>
<b>5.4.5</b>	<b>Blood glucose measurement</b>	<b>132</b>
<b>5.4.6</b>	<b>Result and Discussion</b>	<b>132</b>
<b>5.4.7</b>	<b>Conclusion</b>	<b>137</b>
<b>5.5</b>	<b>Five daily sessions of blood glucose measurement in a healthy normal and a diabetic subject</b>	<b>137</b>
<b>5.5.1</b>	<b>Introduction</b>	<b>137</b>
<b>5.5.2</b>	<b>Study subjects</b>	<b>138</b>
<b>5.5.3</b>	<b>Experimental protocol</b>	<b>138</b>
<b>5.5.4</b>	<b>Blood glucose measurement</b>	<b>138</b>

5.5.5	Result and Discussion	138
5.5.6	Conclusion	142
5.6	Blood Glucose and Glycated Hemoglobin relationship	142
5.6.1	Introduction	142
5.6.2	Study subjects	143
5.6.3	Experimental protocol	143
5.6.4	Invasive and Noninvasive determination of fasting blood glucose levels	144
5.6.5	Glycated Hemoglobin (HbA1c) levels measurement	144
5.6.6	Result and Discussion	145
5.6.7	Conclusion	151
5.7	Blood glucose and blood pressure relationship	151
5.7.1	Introduction	151
5.7.2	Study subjects	151
5.7.3	Experimental protocol	151
5.7.4	Blood pressure and blood glucose measurement	152
5.7.4.1	Blood pressure measurement	152
5.7.4.2	Blood glucose measurement	153
5.7.5	Result and Discussion	153
5.7.5.1	Stage I	153
5.7.5.2	Stage II	155
5.7.5.3	Stage III	157
5.7.6	Conclusion	164
5.8	Extended clinical study using OGTT and Random Blood Glucose Level Tests	164
5.8.1	Introduction	164
5.8.2	Study subjects	165
5.8.3	Experimental Procedures	165
5.8.4	Result and Discussion	166
5.8.4.1	Oral glucose tolerance test based result analysis	166
5.8.4.2	Random blood glucose test based analysis	171
5.8.5	Conclusion	175

---

<b>6. DISCUSSION</b>	<b>176-205</b>
----------------------	----------------

---

6.1	Introduction	177
6.2	Overall result comparison and evaluation	178
6.2.1	Clarke Error Grid Analysis	178
6.2.2	Parkes Error Grid Analysis	181
6.2.3	Accuracy Measure based analysis	183

<b>6.2.4</b>	Pearson correlation coefficient analysis	<b>190</b>
<b>6.2.5</b>	Rank correlation coefficients analysis	<b>193</b>
<b>6.2.6</b>	Bland-Altman Plot	<b>195</b>
<b>6.2.7</b>	Mountain plot	<b>197</b>
<b>6.2.8</b>	Linear model validity	<b>199</b>
<b>6.2.9</b>	Independent sample t-tests	<b>200</b>
<b>6.2.10</b>	Deming Regression	<b>202</b>
<b>6.2.11</b>	ISO compliance	<b>203</b>
<b>6.3</b>	Conclusion	<b>205</b>

---

## **7. CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE WORK 207-211**

---

<b>7.1</b>	Conclusions	<b>208</b>
<b>7.2</b>	Recommendations for future work	<b>210</b>

<b>REFERENCES</b>	<b>212-229</b>
<b>APPENDICES (AI,AII,AIII)</b>	<b>230-234</b>
<b>LIST OF PAPERS, PATENT, AND AWARD PUBLICATIONS</b>	<b>235-237</b>
<b>PERSONAL PROFILE</b>	



## **List of Tables**

	<b>Page No.</b>
<b>2.1</b>	Invasive blood glucose meters <b>15</b>
<b>2.2</b>	Various noninvasive techniques for blood glucose monitoring <b>32</b>
<b>2.3</b>	10% Intralipid suspension constituents <b>47</b>
<b>3.1</b>	Absorption characteristics corresponding to the stretch and vibration patterns of the bonds present in the glucose molecule <b>57</b>
<b>3.2</b>	Glucose sensitivity analysis at 940 nm wavelength <b>62</b>
<b>3.3</b>	Model EDC-20 of Edkits Electronics (Sine wave signal generator) <b>68</b>
<b>3.4</b>	Modulating sine wave signal characteristics <b>69</b>
<b>3.5</b>	Testronix Model-72 (Sine-Square Oscillator) <b>70</b>
<b>3.6</b>	Carrier sine wave signal characteristics <b>71</b>
<b>3.7</b>	AD633 features and benefits <b>72</b>
<b>3.8</b>	Amplitude Modulated Signal characteristics <b>74</b>
<b>3.9</b>	Waveform features as received by the USR unit <b>77</b>
<b>3.10</b>	Square wave signal characteristics <b>78</b>
<b>3.11</b>	The output signal parameters as acquired from the fingertip of the study subject <b>85</b>
<b>3.12</b>	Performance assessment parameters <b>98</b>
<b>5.1</b>	Clarke Error Grid Analysis of Reference (Invasive) and Predicted (Noninvasive) Blood Glucose Levels as acquired during OGTT over healthy subjects. <b>116</b>
<b>5.2</b>	Performance summary and comparison with other noninvasive techniques and CGMS(s) based published data. <b>117</b>
<b>5.3</b>	Clarke Error Grid Analysis of Reference (Invasive) and Predicted (Noninvasive) Blood Glucose Levels. <b>122</b>
<b>5.4</b>	Performance summary and comparison with other noninvasive techniques and CGMS(s) based published data. <b>123</b>
<b>5.5</b>	Clarke Error Grid Analysis of Reference (Invasive) and Predicted (Noninvasive) Blood Glucose Levels. <b>128</b>
<b>5.6</b>	Performance summary and comparison with other noninvasive techniques and CGMS(s) based published data. <b>129</b>
<b>5.7</b>	Clarke Error Grid Analysis of Reference (Invasive) and Predicted (Noninvasive) Blood Glucose Levels. <b>135</b>
<b>5.8</b>	Performance summary and comparison with other noninvasive techniques and CGMS(s) based published data. <b>136</b>
<b>5.9</b>	Clarke Error Grid Analysis of Reference (Invasive) and Predicted (Noninvasive) Blood Glucose Levels. <b>140</b>
<b>5.10</b>	Performance summary and comparison with other noninvasive techniques and CGMS(s) based published data. <b>141</b>

<b>5.11</b>	Blood Glucose Levels and corresponding HbA1c levels	<b>143</b>
<b>5.12</b>	Reference (invasive), predicted (noninvasive) fasting blood glucose values and its corresponding GHb% and, HbA <sub>1c</sub> % values as obtained from the healthy subjects	<b>145</b>
<b>5.13</b>	Reference (invasive), predicted (noninvasive) fasting blood glucose values and its corresponding GHb% and, HbA <sub>1c</sub> % values as obtained from the diabetic subjects	<b>146</b>
<b>5.14</b>	Clarke Error Grid Analysis of Reference (Invasive) and Predicted (Noninvasive) Blood Glucose Levels.	<b>149</b>
<b>5.15</b>	Performance summary and comparison with other noninvasive techniques and CGMS(s) based published data.	<b>150</b>
<b>5.16</b>	Blood pressure classification in adult subjects	<b>152</b>
<b>5.17</b>	Fasting stage blood glucose and blood pressure values of the healthy normal subjects (I to V) as observed during all the three consecutive days of the clinical study.	<b>154</b>
<b>5.18</b>	Fasting stage blood glucose and blood pressure values of the diabetic subjects (VI to X) as observed during all the three consecutive days of the clinical study.	<b>155</b>
<b>5.19</b>	Postprandial stage blood glucose and blood pressure values of the normal subjects (I to V) as observed during all the three consecutive days of the clinical study.	<b>156</b>
<b>5.20</b>	The postprandial stage blood glucose and blood pressure values of the diabetic subjects (VI to X) as observed during all the three consecutive days of the clinical study.	<b>157</b>
<b>5.21</b>	Random stage blood glucose and blood pressure values of the healthy normal Subjects (I to V) as observed during all the three consecutive days of the clinical study.	<b>158</b>
<b>5.22</b>	Random stage blood glucose and blood pressure values of the diabetic subjects (VI to X) as observed during all the three consecutive days of the clinical study.	<b>159</b>
<b>5.23</b>	Clarke Error Grid Analysis of Reference (Invasive) and Predicted (Noninvasive) Blood Glucose Levels.	<b>162</b>
<b>5.24</b>	Performance summary and comparison with other noninvasive techniques and CGMS(s) based published data.	<b>163</b>
<b>5.25</b>	Clarke Error Grid Analysis of Reference (Invasive) and Predicted (Noninvasive) Blood Glucose Levels.	<b>169</b>
<b>5.26</b>	Performance summary and comparison with other noninvasive techniques and CGMS(s) based published data.	<b>170</b>
<b>5.27</b>	Clarke Error Grid Analysis of Reference (Invasive) and Predicted (Noninvasive) Blood Glucose Levels.	<b>173</b>

<b>5.28</b>	Performance summary and comparison with other noninvasive techniques and CGMS(s) based published data.	<b>174</b>
<b>6.1</b>	Clarke Error Grid Analysis of Reference (Invasive) and Predicted (Noninvasive) Blood Glucose Levels	<b>179</b>
<b>6.2</b>	Performance comparison of non-invasive blood glucose measurement-techniques and electrochemical CGMS utilizing Clarke Error Grid Analysis	<b>180</b>
<b>6.3</b>	Parkes Error Grid Analysis of Reference (Invasive) and Predicted (Noninvasive) Blood Glucose Levels	<b>183</b>
<b>6.4</b>	Accuracy measure based performance comparison of non-invasive blood glucose measurement-techniques, and Electrochemical CGMS(s) utilizing Mean Absolute Error (MAE)	<b>185</b>
<b>6.5</b>	Accuracy measure based performance comparison of non-invasive blood glucose measurement-techniques and Electrochemical-CGMS(s) utilizing Percentage of Mean Absolute Relative Error (%MARE)	<b>186</b>
<b>6.6</b>	Accuracy measure based performance comparison of our non-invasive blood glucose Technique to Electrochemical/Micro-dialysis based CGMS(s) utilizing Median Absolute Error (MdAE).	<b>187</b>
<b>6.7</b>	Accuracy measure based performance comparison of non-invasive blood glucose measurement-techniques and Electrochemical-CGMS(s) utilizing Percentage of Median Absolute Relative Error (%MdARE)	<b>188</b>
<b>6.8</b>	Accuracy measure based performance comparison of non-invasive blood glucose measurement-techniques utilizing Root Mean Squared Error (RMSE).	<b>189</b>
<b>6.9</b>	Accuracy measure based performance comparison of non-invasive blood glucose measurement-techniques utilizing Standard Error of Prediction (SEP)	<b>190</b>
<b>6.10</b>	Pearson correlation coefficient (r) analysis	<b>191</b>
<b>6.11</b>	Performance measures of different blood glucose measuring techniques classified based on their degree of invasiveness	<b>192</b>
<b>6.12</b>	Rank Correlation coefficients Analysis	<b>194</b>
<b>6.13</b>	Bland-Altman Plot based analysis	<b>196</b>
<b>6.14</b>	Mountain Plot based analysis	<b>198</b>
<b>6.15</b>	Linear model validity	<b>199</b>
<b>6.16</b>	Independent samples t-test and Welch-test	<b>201</b>
<b>6.17</b>	Deming Regression Analysis	<b>202</b>
<b>6.18</b>	Total Error Limits: ISO 15197-2013	<b>204</b>

## List of Figures

	<b>Page No.</b>
<b>1.1</b> Major long-term medical complications in diabetic subjects	<b>2</b>
<b>1.2</b> The number of research articles on glucose monitoring throughout the stated period	<b>3</b>
<b>2.1</b> Diabetes Mellitus classification	<b>12</b>
<b>2.2</b> Invasive blood glucometers of (a) Roche Diagnostics (b) LifeScan (c) Abbott (d) Bayer HealthCare	<b>14</b>
<b>2.3</b> Major compositions of the human blood	<b>43</b>
<b>2.4</b> The D-Glucose transformation phenomenon	<b>44</b>
<b>2.5</b> Structural morphology of the human skin	<b>45</b>
<b>3.1</b> Absorption spectra of major intracellular absorbers	<b>57</b>
<b>3.2</b> Absorption cross-section of oxyhemoglobin and reduced hemoglobin at Red-NIR region	<b>58</b>
<b>3.3</b> Absorption spectrum of glucose dissolved in water within the spectral range extending from 900 nm to 2400 nm	<b>58</b>
<b>3.4</b> Absorption spectrum of water and glucose in water from 800 nm to 1400 nm	<b>58</b>
<b>3.5</b> Mini-spectrometer of Avantes Inc.,USA	<b>59</b>
<b>3.6</b> Absorption profile of 10% Dextrose (glucose)-distill water within 300 nm to 1050 nm	<b>60</b>
<b>3.7</b> (a) Digital spectrophotometer of M.S Electronics Pvt. Ltd. (India) and (b) Absorption spectra of glucose in distill water between 900 nm to 980 nm	<b>62</b>
<b>3.8</b> The sine wave modulating signal	<b>64</b>
<b>3.9</b> The modulated carrier wave signal	<b>64</b>
<b>3.10</b> Simple depiction of Amplitude Modulated sine wave	<b>65</b>
<b>3.11</b> Amplitude Modulator with input and output signals	<b>66</b>
<b>3.12</b> Block diagram of noninvasive technique based prototype (MUS-IR) unit.	<b>67</b>
<b>3.13</b> Modulating sine wave signal	<b>69</b>
<b>3.14</b> Carrier sine wave signal	<b>71</b>
<b>3.15</b> Functional block diagram of AD633	<b>73</b>
<b>3.16</b> Amplitude Modulation circuit for providing modulation input to the Ultrasound Transmitter unit.	<b>73</b>
<b>3.17</b> Amplitude Modulated signal waveform	<b>74</b>
<b>3.18</b> Amplitude Modulated waveform pattern as provided to the finger holder.	<b>76</b>
<b>3.19</b> The output waveform pattern from the USR unit as recorded by DSO	<b>76</b>

<b>3.20</b>	Finger holder probe of our noninvasive technique based prototype unit.	<b>77</b>
<b>3.21</b>	Square wave signal	<b>78</b>
<b>3.22</b>	Typical spectral intensity distribution of the IR LED used in our prototype	<b>79</b>
<b>3.23</b>	Infrared photodiode circuit diagram	<b>80</b>
<b>3.24</b>	Peak-to-peak amplitude spectrum (in FFT domain) measured at 940 nm from solutions with changing glucose concentration.	<b>82</b>
<b>3.25</b>	The peak-to-peak amplitude in FFT domain relationship with varying glucose concentration in fasting and 2 hour postprandial in-vitro samples	<b>83</b>
<b>3.26</b>	The typical output signal acquired from the fingertip of the study subject	<b>85</b>
<b>3.27</b>	The peak amplitude (mV) spectrum in the FFT domain	<b>86</b>
<b>3.28</b>	The observed signal of the study subject in absence of amplitude-modulated ultrasound in our noninvasive technique based prototype during before meal intake session	<b>87</b>
<b>3.29</b>	The observed peak amplitude spectrum from the study subject in absence of amplitude-modulated ultrasound in our noninvasive technique based prototype during before meal intake session	<b>88</b>
<b>3.30</b>	The observed signal from the study subject in presence of amplitude-modulated ultrasound in our prototype during before meal intake session	<b>88</b>
<b>3.31</b>	The observed peak amplitude spectrum from the study subject in presence of amplitude-modulated ultrasound in our noninvasive technique based prototype during before meal intake session	<b>89</b>
<b>3.32</b>	The observed peak amplitude spectrum from the study subject in presence of amplitude-modulated ultrasound in our noninvasive technique based prototype during one hour after meal intake session.	<b>89</b>
<b>3.33</b>	The observed peak amplitude spectrum from the study subject in presence of amplitude-modulated ultrasound in our noninvasive technique based prototype during one hour after meal intake session	<b>90</b>
<b>3.34</b>	The in-vivo signals based peak amplitude spectral variations in the FFT domain with respect to change in the blood glucose levels during fasting and 2-hour postprandial stages.	<b>90</b>
<b>3.35</b>	Accu-Chek Active of Roche Diagnostics GmbH, Mannheim, Germany (Invasive Glucometer) for Reference Blood Glucose Level measurement in human subjects	<b>93</b>
<b>3.36</b>	Our Noninvasive technique based prototype (MUS-IR) unit	<b>94</b>
<b>3.37</b>	Our noninvasive technique based prototype unit for Predicted (Noninvasive) Blood Glucose Level measurement in human subjects	<b>95</b>

<b>3.38</b>	Clarke Error Grid plot	<b>96</b>
<b>4.1</b>	Diagrammatic representation of the effect of glucose concentration on light transmission phenomenon	<b>100</b>
<b>4.2</b>	Flowchart for quantification of glucose level induced light transmission	<b>102</b>
<b>4.3</b>	Absolute value calculation from the signal waveform as acquired from the healthy subject	<b>104</b>
<b>4.4</b>	Absolute value calculation from the signal waveform as acquired from the diabetic subject	<b>104</b>
<b>4.5</b>	Square value calculation from the signal waveform as acquired from the healthy subject.	<b>105</b>
<b>4.6</b>	Square value calculation from the signal waveform as acquired from the diabetic subject	<b>106</b>
<b>4.7</b>	Absolute value peak to peak as obtained from Healthy and Diabetic Subjects	<b>107</b>
<b>4.8</b>	Square values peak to peak as obtained from the Healthy and Diabetic Subjects	<b>108</b>
<b>4.9</b>	Invasive Random Blood Glucose Levels as obtained from Healthy and Diabetic Subjects	<b>108</b>
<b>5.1</b>	<b>(a)</b> The observed signal as acquired from the subject 1 at 0 min and <b>(b)</b> its corresponding peak amplitude spectrum in the FFT domain	<b>113</b>
<b>5.2</b>	<b>(a)</b> The observed signal as acquired from the subject 1 at 60 min and <b>(b)</b> its corresponding peak amplitude spectrum in the FFT domain	<b>114</b>
<b>5.3</b>	<b>(a)</b> The observed signal as acquired from the subject 1 at 120 min and <b>(b)</b> its corresponding peak amplitude spectrum in the FFT domain	<b>114-115</b>
<b>5.4</b>	OGTT based time dependent sequential variations in the blood glucose levels; error bars indicate $\pm 5$ percentage error.	<b>115</b>
<b>5.5</b>	Clarke Error Grid Analysis plot as obtained from the OGTT investigation.	<b>116</b>
<b>5.6</b>	The effect of 25 gm/100 ml glucose solution (w/v) on the fasting BGL; error bars indicate $\pm 5$ percentage error.	<b>120</b>
<b>5.7</b>	The effect of 50 gm/100 ml glucose solution (w/v) on the fasting BGL; error bars indicate $\pm 5$ percentage error.	<b>120</b>
<b>5.8</b>	The effect of 75 gm/100 ml glucose solution (w/v) on the fasting BGL; error bars indicate $\pm 5$ percentage error	<b>121</b>
<b>5.9</b>	Clarke Error Grid Analysis	<b>122</b>
<b>5.10</b>	BGL after meal intake in healthy and pre-diabetic subjects; error bars indicate $\pm 5$ percentage error.	<b>126</b>
<b>5.11</b>	BGL after 75 gm/100 ml glucose intake in healthy and pre-diabetic subjects; error bars indicate $\pm 5$ percentage error.	<b>127</b>
<b>5.12</b>	Clarke Error Grid Analysis	<b>128</b>

<b>5.13</b>	R-BGL (Invasive) and P-BGL (Noninvasive) blood glucose levels of the healthy subjects during Fasting, Postprandial, and Random stage; error bars indicate $\pm 5$ percentage error.	<b>132</b>
<b>5.14</b>	R-BGL (Invasive) and P-BGL (Noninvasive) blood glucose levels of the Type I Diabetic subjects during Fasting, Postprandial, and Random stage; error bars indicate $\pm 5$ percentage error.	<b>133</b>
<b>5.15</b>	R-BGL (Invasive) and P-BGL (Noninvasive) blood glucose levels of the Type II Diabetic subjects during Fasting, Postprandial, and Random stages; error bars indicate $\pm 5$ percentage error.	<b>134</b>
<b>5.16</b>	Clarke Error Grid Analysis	<b>135</b>
<b>5.17</b>	The Blood Glucose Level values as obtained by the Predicted (noninvasive) and Reference (invasive) methods from the normal subject during 5 daily sessions of fasting, postprandial and random stages; error bars indicate $\pm 5$ percentage error.	<b>139</b>
<b>5.18</b>	The Blood Glucose Level values as obtained by the Predicted (noninvasive) and Reference (invasive) methods from the Type II Diabetic subject during five daily sessions of fasting, postprandial, and random stages; error bars indicate $\pm 5$ percentage error.	<b>139</b>
<b>5.19</b>	Depicts the Clarke Error Grid-based Analysis of the Blood Glucose Level values as obtained from both the Subjects (Normal and Type II Diabetic) during 5 daily sessions of Fasting, Postprandial and Random stages	<b>140</b>
<b>5.20</b>	Reference (invasive), predicted (noninvasive) fasting blood glucose values as obtained from the healthy subjects; error bars indicate $\pm 5$ percentage error.	<b>146</b>
<b>5.21</b>	Reference (invasive), predicted (noninvasive) fasting blood glucose values as obtained from the diabetic subjects; error bars indicate $\pm 5$ percentage error.	<b>147</b>
<b>5.22</b>	HbA1c values of the Healthy (1-10) and Diabetic (11-20) Subjects; error bars indicate $\pm 5$ percentage error.	<b>147</b>
<b>5.23</b>	Clarke Error Grid Analysis of reference (invasive) and predicted (noninvasive) blood glucose measurements as obtained from the normal healthy subjects (1-10) and diabetic subjects (11-20) altogether respectively; error bars indicate $\pm 5$ percentage error.	<b>148</b>
<b>5.24</b>	The relationship between blood glucose and blood pressure values of healthy normal subject II as observed during Day 1 of the clinical study; error bars indicate $\pm 5$ percentage error.	<b>160</b>
<b>5.25</b>	The relationship between Blood Glucose Levels and Blood Pressure values of Diabetic Subject IX respectively; error bars indicate $\pm 5$ percentage error.	<b>161</b>

<b>5.26</b>	The Clarke Error Grid Analysis of the blood glucose levels as obtained from Healthy Normal (I to V) and Diabetic (VI to X) Subjects respectively.	<b>162</b>
<b>5.27</b>	OGTT response curve of the study subjects (1 to 5) on 1 <sup>st</sup> day; error bars indicate $\pm 5$ percentage error.	<b>166</b>
<b>5.28</b>	OGTT response curve of the study subjects (6 to 10) on 2 <sup>nd</sup> day; error bars indicate $\pm 5$ percentage error.	<b>166</b>
<b>5.29</b>	OGTT response curve of the study subjects (11 to 15) on 3 <sup>rd</sup> day; error bars indicate $\pm 5$ percentage error.	<b>167</b>
<b>5.30</b>	OGTT response curve of the study subjects (16 to 20) on 4 <sup>th</sup> day; error bars indicate $\pm 5$ percentage error.	<b>167</b>
<b>5.31</b>	OGTT response curve of the study subjects (21 to 25) on 5 <sup>th</sup> day; error bars indicate $\pm 5$ percentage error.	<b>168</b>
<b>5.32</b>	OGTT response curve of the study subjects (26 to 30) on 6 <sup>th</sup> day; error bars indicate $\pm 5$ percentage error.	<b>168</b>
<b>5.33</b>	Clarke Error Grid analysis based plot for reference (invasive) and predicted (noninvasive) blood glucose measurement as obtained from 30 human subjects during OGTT analysis.	<b>169</b>
<b>5.34</b>	Random Blood Glucose tests of the Subjects (1-10); error bars indicate $\pm 5$ percentage error.	<b>171</b>
<b>5.35</b>	Random Blood Glucose tests of the Subjects (11-20); error bars indicate $\pm 5$ percentage error.	<b>172</b>
<b>5.36</b>	Random Blood Glucose tests of the Subjects (21-30); error bars indicate $\pm 5$ percentage error.	<b>172</b>
<b>5.37</b>	Clarke Error Grid analysis based plot for reference (invasive) and predicted (noninvasive) blood glucose measurement as obtained from 30 human subjects during Random blood glucose tests.	<b>173</b>
<b>6.1</b>	Clarke Error Grid Analysis of overall Reference (Invasive) and Predicted (Noninvasive) blood glucose measurement	<b>179</b>
<b>6.2</b>	Parkes Error Grid Analysis of overall Reference (Invasive) and Predicted (Noninvasive) blood glucose measurement	<b>182</b>
<b>6.3</b>	The scatter diagram of Reference and Predicted Blood Glucose Levels	<b>191</b>
<b>6.4</b>	The scatter diagram of Reference and Predicted Blood Glucose Levels	<b>193</b>
<b>6.5</b>	Bland-Altman Plot based analysis	<b>195</b>
<b>6.6</b>	Mountain Plot based analysis	<b>197</b>
<b>6.7</b>	Deming Regression based analysis	<b>202</b>



## List of Abbreviations

<b>ADA</b>	: American Diabetes Association
<b>AHA</b>	: American Heart Association
<b>AM</b>	: Amplitude Modulation
<b>BGL</b>	: Blood Glucose Level
<b>CE</b>	: Conformité Européenne (European Conformity)
<b>CEG</b>	: Clarke Error Grid
<b>CGMS</b>	: Continuous Glucose Monitoring System
<b>CUSUM</b>	: Cumulative Sum
<b>CI</b>	: Confidence Interval
<b>DCCT</b>	: Diabetes Control and Complications Trial
<b>D-Glucose</b>	: Dextro-Glucose
<b>DM</b>	: Diabetes Mellitus
<b>DSO</b>	: Digital Storage Oscilloscope
<b>EGA</b>	: Error Grid Analysis
<b>EDTA</b>	: Ethylene Di-amine Tetra-acetic Acid
<b>FDA</b>	: Food and Drug Administration
<b>FFT</b>	: Fast Fourier Transform
<b>FM</b>	: Frequency Modulation
<b>FPG</b>	: Fasting Plasma Glucose
<b>GHb</b>	: Glycosylated Hemoglobin
<b>GmbH</b>	: Gesellschaft mit beschränkter Haftung
<b>HbA1c</b>	: Glycated Hemoglobin
<b>IC</b>	: Integrated Circuit
<b>IDF</b>	: International Diabetes Federation
<b>IFG</b>	: Impaired Fasting Glucose
<b>IGT</b>	: Impaired Glucose Tolerance
<b>IMS-BHU</b>	: Institute of Medical Sciences-Banaras Hindu University
<b>IR</b>	: Infra Red
<b>ISO</b>	: International Organization for Standardization
<b>Inc.,</b>	: Incorporation
<b>LASER</b>	: Light Amplification Simulation Emission Radiation
<b>LED</b>	: Light Emitting Diode
<b>MAE</b>	: Mean Absolute Error
<b>%MARE</b>	: Percentage of Mean Absolute Relative Error
<b>MdAE</b>	: Median Absolute Error
<b>%MdARE</b>	: Percentage of Median Absolute Relative Error
<b>MATLAB</b>	: Matrix Laboratory
<b>MIR</b>	: Mid Infra Red

<b>MUS-IR</b>	: Modulated Ultra Sound-Infra Red
<b>NIR</b>	: Near Infra Red
<b>OCT</b>	: Optical Coherence Tomography
<b>OGTT</b>	: Oral Glucose Tolerance Test
<b>PA</b>	: Photo Acoustic
<b>P-BGL</b>	: Predicted-Blood Glucose Level
<b>PBS</b>	: Phosphate Buffer Solution
<b>PP</b>	: Post Prandial
<b>PEG</b>	: Parkes Error Grid
<b>PM</b>	: Phase Modulation
<b>RAD</b>	: Relative Absolute Difference
<b>RBC</b>	: Red Blood Corpuscles
<b>R-BGL</b>	: Reference-Blood Glucose Level
<b>RIGMD</b>	: Reverse Iontophoresis based Glucose Monitoring Device
<b>RMSE</b>	: Root Mean Squared Error
<b>r value</b>	: Correlation Coefficient
<b>SD</b>	: Standard Deviation
<b>SNR</b>	: Signal to Noise Ratio
<b>SEP</b>	: Standard Error of Prediction
<b>TM</b>	: Trade Mark
<b>THb</b>	: Total Hemoglobin
<b>UK</b>	: United Kingdom
<b>UKPSD</b>	: United Kingdom Prospective Diabetes Study
<b>USA</b>	: United States of America
<b>USD</b>	: United States Dollar
<b>US\$</b>	: United States Dollar
<b>USR</b>	: Ultra Sound Receiver
<b>UST</b>	: Ultra Sound Transmitter
<b>UV</b>	: Ultra Violet
<b>WHO</b>	: World Health Organization